Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity.

Coates LC, Orbai AM, Morita A, Benichou O, Kerr L, Adams DH, Shuler CL, Birt J, Helliwell PS.

BMC Rheumatol. 2018 Aug 13;2:24. doi: 10.1186/s41927-018-0030-y. eCollection 2018.

PMID:
30886974
2.

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Feb 15. pii: jrheum.181089. doi: 10.3899/jrheum.181089. [Epub ahead of print]

PMID:
30770518
3.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jan 3. doi: 10.1093/rheumatology/key417. [Epub ahead of print]

PMID:
30608620
4.

Thermodynamics of Adsorption on Graphenic Surfaces from Aqueous Solution.

Azhagiya Singam ER, Zhang Y, Magnin G, Miranda-Carvajal I, Coates L, Thakkar R, Poblete H, Comer J.

J Chem Theory Comput. 2019 Feb 12;15(2):1302-1316. doi: 10.1021/acs.jctc.8b00830. Epub 2019 Jan 11.

PMID:
30592594
5.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Callis Duffin K, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2018 Dec 15. pii: jrheum.181077. doi: 10.3899/jrheum.181077. [Epub ahead of print]

PMID:
30554154
6.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

7.

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.

Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ, Nantel F.

Rheumatology (Oxford). 2018 Dec 4. doi: 10.1093/rheumatology/key359. [Epub ahead of print]

PMID:
30517715
8.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30.

PMID:
30499259
9.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.

PMID:
30499246
10.

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review.

Tucker LJ, Coates LC, Helliwell PS.

Rheumatol Ther. 2019 Mar;6(1):23-32. doi: 10.1007/s40744-018-0132-4. Epub 2018 Nov 23. Review.

11.

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.

Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L.

Ann Rheum Dis. 2019 Feb;78(2):201-208. doi: 10.1136/annrheumdis-2018-214140. Epub 2018 Nov 15.

PMID:
30442648
12.

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC.

Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.

13.

Improving the accuracy and resolution of neutron crystallographic data by three-dimensional profile fitting of Bragg peaks in reciprocal space.

Sullivan B, Archibald R, Langan PS, Dobbek H, Bommer M, McFeeters RL, Coates L, Wang X, Gallmeier F, Carpenter JM, Lynch V, Langan P.

Acta Crystallogr D Struct Biol. 2018 Nov 1;74(Pt 11):1085-1095. doi: 10.1107/S2059798318013347. Epub 2018 Oct 29.

14.

Anomalous X-ray diffraction studies of ion transport in K+ channels.

Langan PS, Vandavasi VG, Weiss KL, Afonine PV, El Omari K, Duman R, Wagner A, Coates L.

Nat Commun. 2018 Oct 31;9(1):4540. doi: 10.1038/s41467-018-06957-w.

15.

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.

Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.

16.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD.

Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22.

PMID:
30360969
17.

Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.

Ye W, Tucker LJ, Coates LC.

Drugs. 2018 Nov;78(16):1705-1715. doi: 10.1007/s40265-018-0994-3. Review.

PMID:
30341684
18.

Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.

Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A.

J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.

PMID:
30323006
19.

Redox manipulation of the manganese metal in human manganese superoxide dismutase for neutron diffraction.

Azadmanesh J, Lutz WE, Weiss KL, Coates L, Borgstahl GEO.

Acta Crystallogr F Struct Biol Commun. 2018 Oct 1;74(Pt 10):677-687. doi: 10.1107/S2053230X18011299. Epub 2018 Sep 21.

20.

Cryo-neutron crystallographic data collection and preliminary refinement of left-handed Z-DNA d(CGCGCG).

Harp JM, Coates L, Sullivan B, Egli M.

Acta Crystallogr F Struct Biol Commun. 2018 Oct 1;74(Pt 10):603-609. doi: 10.1107/S2053230X1801066X. Epub 2018 Sep 21.

PMID:
30279310
21.

Preface: Special Topic on Advances in Modern Neutron Diffraction at Oak Ridge National Laboratory.

Page K, Haberl B, Coates L, Tucker M.

Rev Sci Instrum. 2018 Sep;89(9):092601. doi: 10.1063/1.5055785. No abstract available.

PMID:
30278697
22.

A suite-level review of the neutron single-crystal diffraction instruments at Oak Ridge National Laboratory.

Coates L, Cao HB, Chakoumakos BC, Frontzek MD, Hoffmann C, Kovalevsky AY, Liu Y, Meilleur F, Dos Santos AM, Myles DAA, Wang XP, Ye F.

Rev Sci Instrum. 2018 Sep;89(9):092802. doi: 10.1063/1.5030896.

PMID:
30278686
23.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

24.

Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?

Tucker LJ, Ye W, Coates LC.

Curr Rheumatol Rep. 2018 Sep 18;20(11):71. doi: 10.1007/s11926-018-0781-x. Review.

25.

What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?

Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS.

J Rheumatol. 2019 Jan;46(1):38-42. doi: 10.3899/jrheum.180267. Epub 2018 Sep 15.

PMID:
30219765
26.

Defining the Specificity of Carbohydrate-Protein Interactions by Quantifying Functional Group Contributions.

Sood A, Gerlits OO, Ji Y, Bovin NV, Coates L, Woods RJ.

J Chem Inf Model. 2018 Sep 24;58(9):1889-1901. doi: 10.1021/acs.jcim.8b00120. Epub 2018 Aug 22.

PMID:
30086239
27.

The rise of neutron cryo-crystallography.

Kwon H, Langan PS, Coates L, Raven EL, Moody PCE.

Acta Crystallogr D Struct Biol. 2018 Aug 1;74(Pt 8):792-799. doi: 10.1107/S205979831800640X. Epub 2018 Jul 24. Review.

28.

A review of the global distribution of Alexandrium minutum (Dinophyceae) and comments on ecology and associated paralytic shellfish toxin profiles, with a focus on Northern Europe.

Lewis AM, Coates LN, Turner AD, Percy L, Lewis J.

J Phycol. 2018 Oct;54(5):581-598. doi: 10.1111/jpy.12768. Epub 2018 Sep 12. Review.

PMID:
30047623
29.

Variability and profiles of lipophilic toxins in bivalves from Great Britain during five and a half years of monitoring: Okadaic acid, dinophysis toxins and pectenotoxins.

Dhanji-Rapkova M, O'Neill A, Maskrey BH, Coates L, Teixeira Alves M, Kelly RJ, Hatfield RG, Rowland-Pilgrim SJ, Lewis AM, Algoet M, Turner AD.

Harmful Algae. 2018 Jul;77:66-80. doi: 10.1016/j.hal.2018.05.011. Epub 2018 Jun 19.

PMID:
30005803
30.

Personalized medicine - a new reality in psoriatic arthritis?

Al-Mossawi H, Coates LC.

Nat Rev Rheumatol. 2018 Aug;14(8):449-451. doi: 10.1038/s41584-018-0043-3. No abstract available.

PMID:
29991813
31.

Optimizing Crystal Size of Photosystem II by Macroseeding: Toward Neutron Protein Crystallography.

Hussein R, Ibrahim M, Chatterjee R, Coates L, Müh F, Yachandra VK, Yano J, Kern J, Dobbek H, Zouni A.

Cryst Growth Des. 2018 Jan 3;18(1):85-94. doi: 10.1021/acs.cgd.7b00878. Epub 2017 Nov 13.

32.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

PMID:
29928910
33.

Clinical management of psoriatic arthritis.

Van den Bosch F, Coates L.

Lancet. 2018 Jun 2;391(10136):2285-2294. doi: 10.1016/S0140-6736(18)30949-8. Epub 2018 Jun 1. Review.

PMID:
29893227
34.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
35.

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.

Gottlieb AB, Coates LC, van Mens LJJ, Armstrong AW, Merola JF.

J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.

PMID:
29858353
36.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
37.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
38.

Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten DLP, Coates LC.

Ann Rheum Dis. 2018 May 18. pii: annrheumdis-2018-213618. doi: 10.1136/annrheumdis-2018-213618. [Epub ahead of print] No abstract available.

PMID:
29776975
39.

Elucidation of Hydrogen Bonding Patterns in Ligand-Free, Lactose- and Glycerol-Bound Galectin-3C by Neutron Crystallography to Guide Drug Design.

Manzoni F, Wallerstein J, Schrader TE, Ostermann A, Coates L, Akke M, Blakeley MP, Oksanen E, Logan DT.

J Med Chem. 2018 May 24;61(10):4412-4420. doi: 10.1021/acs.jmedchem.8b00081. Epub 2018 May 3.

40.

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis.

Coates LC, Savage LJ, Chinoy H, Laws PM, Lovell CR, Korendowych E, Mahmood F, Mathieson HR, McGonagle D, Warren RB, Waxman R, Helliwell PS.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1530-1534. doi: 10.1111/jdv.14971. Epub 2018 May 9.

PMID:
29578628
41.

Considerations for the definition of remission criteria in psoriatic arthritis.

Mease PJ, Coates LC.

Semin Arthritis Rheum. 2018 Jun;47(6):786-796. doi: 10.1016/j.semarthrit.2017.10.021. Epub 2017 Oct 31. Review.

42.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).

Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB.

RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.

43.

Fatal Canine Intoxications Linked to the Presence of Saxitoxins in Stranded Marine Organisms Following Winter Storm Activity.

Turner AD, Dhanji-Rapkova M, Dean K, Milligan S, Hamilton M, Thomas J, Poole C, Haycock J, Spelman-Marriott J, Watson A, Hughes K, Marr B, Dixon A, Coates L.

Toxins (Basel). 2018 Feb 26;10(3). pii: E94. doi: 10.3390/toxins10030094.

44.

Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.

Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-1535. doi: 10.1002/acr.23537. Epub 2018 Sep 1.

PMID:
29409133
45.

Analysis of Microcystins in Cyanobacterial Blooms from Freshwater Bodies in England.

Turner AD, Dhanji-Rapkova M, O'Neill A, Coates L, Lewis A, Lewis K.

Toxins (Basel). 2018 Jan 11;10(1). pii: E39. doi: 10.3390/toxins10010039.

46.

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates LC, Kishimoto M, Gottlieb A, Shuler CL, Lin CY, Lee CH, Mease PJ.

RMD Open. 2017 Dec 22;3(2):e000567. doi: 10.1136/rmdopen-2017-000567. eCollection 2017.

47.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

48.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

49.

Molecular Mechanism of Enzymatic Chlorite Detoxification: Insights from Structural and Kinetic Studies.

Schaffner I, Mlynek G, Flego N, Pühringer D, Libiseller-Egger J, Coates L, Hofbauer S, Bellei M, Furtmüller PG, Battistuzzi G, Smulevich G, Djinović-Carugo K, Obinger C.

ACS Catal. 2017 Nov 3;7(11):7962-7976. doi: 10.1021/acscatal.7b01749. Epub 2017 Oct 13.

50.

Current concepts and unmet needs in psoriatic arthritis.

Mahmood F, Coates LC, Helliwell PS.

Clin Rheumatol. 2018 Feb;37(2):297-305. doi: 10.1007/s10067-017-3908-y. Epub 2017 Nov 13. Review.

PMID:
29134513

Supplemental Content

Loading ...
Support Center